Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CSLLY)

Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process

PR Newswire August 23, 2018

IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients

PR Newswire August 23, 2018

GISAID announces a major contribution from Seqirus to support open and rapid sharing of influenza virus data

PR Newswire Asia July 26, 2018

A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant

PR Newswire June 22, 2018

IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes

PR Newswire May 31, 2018

Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"

PR Newswire May 14, 2018

Patient Advocacy Groups Focus On Key Issues Affecting Patients

PR Newswire April 26, 2018

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

PR Newswire April 20, 2018

The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months

PR Newswire April 19, 2018

Nasdaq Hosted 2nd Nasdaq International Designation Virtual Investor Conference

GlobeNewswire April 3, 2018

CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors

PR Newswire March 23, 2018

Forbes Magazine Names CSL Limited Among Top 50 Employers in the World

PR Newswire March 20, 2018

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PR Newswire March 16, 2018

CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks

PR Newswire March 15, 2018

CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines

PR Newswire Europe Non Regulatory March 13, 2018

CSL and Vitaeris Announce Strategic Partnership with Option to Acquire

PR Newswire December 5, 2017

CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy

PR Newswire December 4, 2017

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors

PR Newswire December 4, 2017

Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PR Newswire November 9, 2017

Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting

PR Newswire October 29, 2017